Market research
1S9.F Seres Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3M
- P/E ratio
- 0.0
- Analyst target
- 20.57
- Dividend yield
- Not available
- Beta
- 2.53
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US81750R1023
- Market cap
- 3M
- P/E ratio
- 0.0
- Analyst target
- 20.57
- Dividend yield
- Not available
- Beta
- 2.53
About
About Seres Therapeutics, Inc
Seres Therapeutics, Inc., a clinical-stage company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. The company develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's product candidate is VOWST, the first FDA-approved orally administered microbiome therapeutic. Its product pipeline also includes SER-155, an investigational, oral, live biotherapeutic designed to decolonize gastrointestinal, or GI, pathogens, improve epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, or BSIs, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation, or allo-HSCT. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it develops SER-147, an investigational live biotherapeutic designed to prevent bacterial bloodstream and spontaneous bacterial peritonitis, or SBP, infections in patients with metabolic disease, including clinical liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 1S9.F discussion.
5 years, 4 months ago
Seres Therapeutics, Inc is currently in a long term downtrend where the price is trading 18.8% below its 200 day moving average.
From a valuation standpoint, the stock is 96.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 51.0.
Seres Therapeutics, Inc's total revenue rose by 130.4% to $18M since the same quarter in the previous year.
Its net income has increased by 2.8% to $-18M since the same quarter in the previous year.
Finally, its free cash flow fell by 27.1% to $-18M since the same quarter in the previous year.
Based on the above factors, Seres Therapeutics, Inc gets an overall score of 3/5.